Compositions and methods for the treatment of allergy
Inventors
Szabady, Rose L. • Olle, Bernat • Roberts, Bruce
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10507221-B2
Publication Date
2019-12-17
Expiration Date
Abstract
Provided herein are compositions and methods for the treatment of allergy, such as food allergy. Also provided herein are compositions and methods for modulating an immune response associated with allergy and/or inducing immune tolerance or desensitization to an allergy, such as a food allergy.
Core Innovation
The invention relates to a method of treating a food allergy by orally administering to a subject in need thereof a therapeutically effective amount of a composition comprising a purified bacterial mixture. The mixture consists of 7 bacterial strains, where each strain comprises one of 16S rDNA sequences having at least 99.5% sequence identity to SEQ ID NOs: 1-5, 7, and 8, and the composition includes 1 strain comprising each of the 16S rDNA sequences.
The disclosed approach evaluates allergic outcomes including Foxp3+ regulatory T cells and serum IgE, and short chain fatty acids such as butyrate and acetate in connection with experimental food allergy and anaphylaxis. The document content also includes reduced Th2 responses and mast cell markers, alongside IgE outcomes, and describes multi-strain bacterial compositions in germ-free and SPF mouse models of allergy.
The provided content further discusses decoupling Treg induction from butyrate production and microbiome shifts, using sequencing and PCA. The composition formats described include multiple food and beverage vehicle categories and formats suitable for oral administration.
Claims Coverage
One inventive feature is identified in the provided partial content.
Oral administration of a purified seven-strain bacterial mixture for food allergy treatment
Orally administering to a subject in need thereof a therapeutically effective amount of a composition comprising a purified bacterial mixture consisting of 7 bacterial strains, where each strain comprises one of 16S rDNA sequences having at least 99.5% sequence identity to SEQ ID NOs: 1-5, 7, and 8, with 1 strain comprising each sequence.
The claim coverage centers on oral administration of a purified seven-strain bacterial mixture defined by specific 16S rDNA sequence identity for treating food allergy.
Stated Advantages
Increased regulatory T cells (FoxP3+).
Suppression of IgE and Th2 immune responses.
Supports immune tolerance and desensitization.
Enhanced engraftment/colonization and colonization duration with antibiotic pretreatment.
Treats a food allergy by oral administration of a purified seven-strain bacterial mixture.
Provides experimental protection against experimental food allergy and anaphylaxis with reduced Th2 responses and IgE outcomes.
Is associated with induction or assessment of Foxp3+ regulatory T cells.
Is associated with assessment of short chain fatty acids such as butyrate and acetate in connection with allergic outcomes.
Documented Applications
Treating a food allergy by orally administering a therapeutically effective amount of a purified bacterial mixture.
Treating or targeting specific food-allergy types selected from nut allergy, fish allergy, wheat allergy, milk allergy, peanut allergy, tree nut allergy, shellfish allergy, soy allergy, seed allergy, sesame seed allergy, and egg allergy.
Modulating intestinal/colon delivery using enteric polymer delivery and formulated bacterial compositions such as lyophilized, spray-dried, or spore form.
Oral treatment of a subject with a food allergy.
Use in experimental food allergy and anaphylaxis assessment in germ-free and SPF mouse models, including measurement of Foxp3+ regulatory T cells and serum IgE outcomes.
Incorporation into food and beverage vehicles and multiple formulation formats, including powders, granules, tablets, capsules, liquids, pastes, and jellies, to deliver disclosed bacterial strains.
Interested in licensing this patent?